Table 1
| Disease Site |
Study | Study Name | Open Date | Number of Active Institutions |
Number of Current IRBs |
|---|---|---|---|---|---|
| BREAST | S1418 | Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 15-NOV-16 | 412 | 204 |
| S1706 | Breast, Inflammatory, RT +/- Olaparib | 12-SEP-18 | 0 | 92 | |
| A011401 | Breast, adj, Stage II/III HER2-, weight loss | 29-AUG-16 | 382 | 218 | |
| A011502 | Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo | 08-DEC-16 | 0 | 213 | |
| B51 | Breast, Regional Nodal XRT | 22-AUG-13 | 289 | 160 | |
| EA1131 | Brst, TNBC, Post-op Chemo vs Obs | 20-AUG-14 | 289 | 127 | |
| EA1181 | BRST, HER2-pCR, Preop THP and Postop HP | 11-FEB-20 | 0 | 59 | |
| MA39 | BREAST, Node-Pos, Reg RT vs No Reg RT | 30-MAY-18 | 0 | 109 | |
| NRGBR003 | Brst,Adj,TNBC,AC -> WP +/- Carbo | 22-JAN-15 | 319 | 158 | |
| NRGBR004 | BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo | 12-MAR-19 | 0 | 27 | |
| CCD | S1703 | Met Breast, STM-monitoring v Usual Care | 16-JUL-18 | 0 | 80 |
| S1916 | Pain, Mets, Opioid Digital Medicine Pilot | 15-OCT-19 | 0 | 8 | |
| ACCL16N1 | Guideline Consistent Treatment AYA ALL | 18-DEC-17 | 0 | 50 | |
| EA1151 | CCD, Tomosynthesis Mammographic Screening | 06-JUL-17 | 0 | 93 | |
| EAQ162CD | CCD, Financial Burden, Colon & Rectal Cancer | 17-MAY-18 | 0 | 69 | |
| EAQ171CD | Smoke Free Support Study 2.0 | 11-APR-19 | 0 | 40 | |
| NHLBIMDS | LEUK, National MDS Study | 05-APR-16 | 219 | 84 | |
| ERLYTX | S1609 | Rare Tumor, Comb Nivo/Ipi | 13-JAN-17 | 341 | 159 |
| EAY131 | MATCH | 12-AUG-15 | 378 | 207 | |
| GI | S1613 | mCRC, Adv/Met, TP vs CETIRI | 09-OCT-17 | 0 | 121 |
| S1815 | Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel | 03-DEC-18 | 0 | 117 | |
| S1922 | Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | 16-DEC-19 | 0 | 47 | |
| A021502 | Colon, Stg III, Chemo +/- Atezol, ATOMIC | 12-SEP-17 | 0 | 171 | |
| A021602 | PANC, Adv PNET Blinded Cabozantinib v Placebo | 18-JUL-18 | 0 | 93 | |
| A021703 | COLON, Adv/Met, Chemo + Std v High dose V-D3 | 30-SEP-19 | 0 | 24 | |
| EA2142 | GI NEC, Adv G3, EP vs TMZ + CAP | 06-NOV-15 | 191 | 83 | |
| EA2165 | Anal, Stg II-III, Nivolumab after CMT | 13-APR-18 | 0 | 136 | |
| NRGGI004 | Colorectal, Stg IV, dMMR Immuno-Therapy | 07-NOV-17 | 0 | 130 | |
| NRGGI005 | COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy | 16-DEC-19 | 0 | 2 | |
| GU | S1602 | Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 07-FEB-17 | 184 | 91 |
| S1802 | Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 17-SEP-18 | 0 | 128 | |
| S1806 | Blad, MIBC, ChemoRT +/- Atezolizumab | 19-APR-19 | 0 | 126 | |
| A031102 | GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 01-JUL-15 | 53 | 37 | |
| A031501 | Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs | 21-SEP-17 | 0 | 139 | |
| A031701 | Bladder, ddGC for MIBC with DDR Tumor Alt | 01-AUG-18 | 0 | 56 | |
| A031702 | GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | 12-APR-19 | 0 | 85 | |
| A031704 | RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | 09-MAY-19 | 0 | 106 | |
| A031803 | Blad, NMIBC, Gemcitabine + MK-3475 | 06-JAN-20 | 0 | 15 | |
| EA8143 | RCC, HR, Surg +/- Nivolumab (PROSPER) | 02-FEB-17 | 0 | 146 | |
| EA8153 | Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) | 08-FEB-18 | 0 | 91 | |
| EA8171 | PROS, newly diagnosed, mpMRI for pre-op stagi | 09-JUL-18 | 0 | 38 | |
| NRGGU002 | Pros, RT + ADT After RP +/- Adj Docetaxel | 30-DEC-16 | 0 | 102 | |
| NRGGU005 | PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT | 16-NOV-17 | 0 | 117 | |
| NRGGU006 | PROS, post-RP PSA, SRT +/- ADT w/Apalutamide | 27-APR-18 | 0 | 129 | |
| LEUK | S1318 | ALL, Age 65+, Ph±, Blinatumomab | 12-JAN-15 | 118 | 45 |
| S1712 | CML, Chronic Phase, TKI +/- Ruxolitinib | 20-JUL-18 | 0 | 68 | |
| A041501 | B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | 01-JUN-17 | 0 | 77 | |
| A041701 | AML, Age 60+, Conv Chemo +/- Uproleselan | 16-JAN-19 | 0 | 58 | |
| A041702 | CLL, Stg I-IV, IO with IM versus IVO | 04-JAN-19 | 0 | 120 | |
| EA9161 | CLL, untreated, IOV vs IO in younger pts | 03-JAN-19 | 0 | 124 | |
| EA9171 | CML, Anti-PD-1 Pembrolizumab + TKIs | 03-OCT-18 | 0 | 2 | |
| LUNG | S1701 | Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | 09-AUG-18 | 0 | 38 |
| S1800A | Non-Match: Ramu + Pembro vs SoC | 17-MAY-19 | 0 | 161 | |
| S1827 | SCLC, MRI Surveillance +/- PCI | 10-JAN-20 | 0 | 83 | |
| S1900A | LOH and/or BRCA: Rucaparib | 28-JAN-19 | 0 | 165 | |
| S1900B | RET Fusion: Selpercatinib (LOXO-292) | 10-FEB-20 | 0 | 110 | |
| S1900C | STK11: Talazoparib + Avelumab | 16-JAN-20 | 0 | 126 | |
| S1914 | NSCLC, High Risk Early Stg, SBRT +/- Atezo | 25-MAR-20 | 0 | 47 | |
| S1929 | ESCLC, SLFN11+, Atezolizumab ± Talazoparib | 15-JUN-20 | 0 | 8 | |
| S1933 | NSCLC, Stg II-III, RT + Atezo | 15-JUN-20 | 0 | 9 | |
| A081105 | ALCHEMIST1, EGFR mut, Erlotinib | 02-JAN-14 | 0 | 211 | |
| A151216 | ALCHEMIST0 - screening | 06-FEB-14 | 388 | 220 | |
| E4512 | ALCHEMIST2, ALK mut, Crizotinib | 18-AUG-14 | 393 | 216 | |
| EA5163 | NSCLC, Immunotherapy +/- 2nd line therapy | 28-FEB-19 | 0 | 125 | |
| LUNGMAP | NSCLC, Adv, Master | 28-JAN-19 | 0 | 188 | |
| NRGCC003 | SCLC, PCI or HA-PCI | 07-DEC-15 | 236 | 129 | |
| NRGLU002 | LUNG, Limited Met NSCLC, MST vs LCT + MST | 07-APR-17 | 0 | 137 | |
| NRGLU005 | LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo | 28-MAY-19 | 0 | 135 | |
| LYMPH | S1608 | FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 10-AUG-17 | 0 | 98 |
| S1826 | HD, Adv, Age 12+, N+AVD vs BV+AVD | 19-JUL-19 | 0 | 131 | |
| A051301 | ABC DLBCL, Auto HCT and Ibrutinib/Placebo | 15-JUL-16 | 177 | 70 | |
| A051701 | LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax | 07-AUG-19 | 0 | 90 | |
| E4412 | HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | 24-JAN-14 | 0 | 56 | |
| EA4151 | Lymph, AHCT +/-Ritux, MRD Neg | 29-AUG-17 | 0 | 75 | |
| EA4181 | MCL, Randomization BR/CR v BR/CR-A v BR-A | 03-OCT-19 | 0 | 33 | |
| MELAN | S1512 | Melan, Adv, Desmoplastic, MK-3475 (pembro) | 20-OCT-16 | 91 | 40 |
| S1607 | MELAN, Adv, T-VEC, MK-3475 | 02-OCT-17 | 0 | 23 | |
| S1616 | MELAN, Adv, Ipilimumab ± Nivolumab | 17-JUL-17 | 0 | 100 | |
| S1801 | Melan, Adv, Adj vs Neoadj Pembrolizumab | 06-DEC-18 | 0 | 130 | |
| EA6134 | Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 15-DEC-15 | 297 | 129 | |
| EA6141 | Melan, Avd, Nivolumab+Ipi ± Sargmostim | 01-MAR-16 | 203 | 80 | |
| EA6174 | Merkel, Adjuvant Pembrolizumab vs Observation | 23-JUL-18 | 0 | 93 | |
| MMYEL | S1803 | MM, Maintenance, Len vs Len/Dara | 27-JUN-19 | 0 | 95 |
| EAA173 | MYEL, SMM, Rd +/- Daratumumab | 30-APR-19 | 0 | 76 | |
| OTHER | A091802 | cSCC, Advanced Avelumab +/- Cetuximab | 17-MAY-19 | 0 | 8 |
| A151804 | irAEs, National Biorepository to Adv Studies | 31-JAN-20 | 0 | 7 | |
| AGCT1532 | Inter/Poor Met GCTs, Accel v Std BEP Chemo | 30-JUL-18 | 0 | 67 | |
| EA3132 | HN SCC, Stg III-IV , Adj RT +/- Cisp | 29-MAR-16 | 0 | 66 | |
| EA3161 | HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo | 20-JUN-19 | 0 | 74 | |
| EAF151 | Brain, GBM, Bev, Blood Volume | 14-APR-17 | 0 | 32 | |
| G0263 | Cerv, Stg I/IIA, adjv RT vs chemoRT | 12-APR-10 | 0 | 56 | |
| N0577 | BRN, Glio,Tem vs Tem+RT vsRT+PVC | 22-SEP-09 | 213 | 86 | |
| NCICOVID | NCI COVID-19 in Cancer Patients Study | 21-MAY-20 | 0 | 27 | |
| NRGBN001 | HN, novel vs. std chemoradiation + chemo | 28-AUG-15 | 0 | 71 | |
| NRGBN003 | Mening, Grd II, Observation vs Irradiation | 14-JUN-17 | 0 | 100 | |
| NRGGY005 | OVAR, Cedir vs Olaparib vs C+O vs Std of Care | 06-FEB-16 | 294 | 123 | |
| NRGHN001 | Nasopharyngeal , Indiviual Tx EBV | 21-APR-14 | 172 | 74 | |
| NRGHN004 | HN, Adv, RT+Durvalumab vs RT+Cetuximab | 12-DEC-17 | 0 | 134 | |
| NRGHN005 | HN, early stg P16-pos, randomize de-intensifi | 10-JUL-19 | 0 | 103 | |
| R0724 | Cervical, Chem+RT +/- Adj. Chemo | 15-JAN-14 | 177 | 69 | |
| PEOLC | S1820 | Rectal, Diet modification to manage GI sx | 09-DEC-19 | 0 | 56 |
| PREV | S1823 | GCT, Obs. Cohort, miRNA371 | 01-JUN-20 | 0 | 14 |
| A211601 | Breast, Stg II-III, Aspirin | 01-AUG-18 | 0 | 65 | |
| SURV | S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol | 15-SEP-17 | 0 | 99 |
| E1Q11 | EROS: Reproductive Health in Cancer Survivors | 30-SEP-15 | 0 | 46 | |
| EA9131 | Leuk, Strategy to decrease early APL deaths | 16-AUG-17 | 0 | 24 | |
| SXQOL | S1614 | HBV in Ca Pts, TAF vs SOC | 21-FEB-19 | 0 | 26 |
| S1714 | CIPN Risk Prediction Cohort Study, Taxanes | 01-MAR-19 | 0 | 58 | |
| A171601 | Breast, ER+ HER2- Met, Palboc + Letroz/Fulves | 15-AUG-18 | 0 | 2 | |
| A221504 | NSCL, Advanced, placebo vs naloxegol | 13-OCT-17 | 0 | 83 | |
| A221505 | Brst, Hypofractionated Post Mast Rad | 01-FEB-18 | 0 | 116 | |
| A221602 | CINV in HEC patients, Olanza +/- Fosapre | 15-OCT-18 | 0 | 66 | |
| A221702 | BREAST, SLN/ALND +/- ARM | 31-MAY-19 | 0 | 70 | |